Protocol Ledger

NCT07509892 · Phase II · RECRUITING

A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

Interventional Phase II clinical trial protocol NCT07509892 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-22 Enrollment: 198 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07509892
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)198 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07509892
Protocol FieldVerified Registry Value
NCT IdentifierNCT07509892
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment198 participants (ESTIMATED)
Registered Start Date2026-06-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07509892
Hospital Research SiteLocationSite Profile
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen UniversityGuangzhou, ChinaOpen Hospital Dossier ->
Shenzhen Second People's HospitalShenzhen, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI